Sendte denne til Malene, Egberts og Skullerud nå, tenkte jeg like godt kunne dele den med alle i disse special times!!
With regards to the first sentence in the email I received from you earlier this month:
“We hope you can appreciate the clarity the comprehensive review hopefully will bring”.
Well, you have sent out a statement and the MCAP is at a level far below most pre-clincial candidates.
Is this based on the clarity the comprehensive review came to? Because the market seem to have concluded on what this review means for the company.
The big problem with that is that market is totally left out in the cold and will be there until august. We actually have no clue on what the company we have invested in thinks after this review.
You have placed the reponsibility to conclude in the hands of 12 000 shareholders, whom mostly have been listening to your previous presentations when they have decided to invest in you or not.
Needless to say we havent heard anything else but positive expectations related to that. The last words from you tells otherwise, and then you go radiosilence for a month or two!
I can not believe that you still maintain that strategy and let the shareholders flee around as headless birds. Where to run, what to believe, are the investments lost, are you sitting on a negative decision that would make this fall even more painful for us?
I know you probably are listening to Radforsk and their podkasts, and there were no doubt about their opinion about this yesterday. Its totally unacceptable to not meet with your shareholders in this times.
If you can not answer any questions due to restrictions that would be fine, but just go to your escape room and leave the market in shock is a very bad decision. That both Elisabeth and Jonas expressed their feelings about.
I will ask you to please reconsider this decision. You are not treating your shareholders with respect and understanding.
We know there are high risks in biotech, but it doesn’t mean that you can leave your shareholders out in the cold when bad and most definitely unclear news hits the market.
Once again I write on behalf of several shareholders.